Discover 97 paid clinical trials in Huntsville, Alabama. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 97
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
for
Major Depressive Disorder
Location: Huntsville AL, Atlanta GA, Bryant AR, Saint Charles MO,
Sponsor: Xenon Pharmaceuticals Inc.
Sex: All
Age: 18 - 70+
Code: NCT07076407
Phase3, Recruiting
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
for
Aortic Stenosis, Calcific, Aortic Valve Stenosis
Location: Huntsville AL, Nashville TN, Atlanta GA, Knoxville TN,
Sponsor: Edwards Lifesciences
Sex: All
Age: 65+
Code: NCT04889872
Recruiting
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
Get alerts for new trials in your area by subscribing now
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
for
Type2Diabetes, ASCVD
Location: Huntsville AL, Nashville TN, Suwanee GA, Johns Creek GA,
Sponsor: Brigham and Women's Hospital
Sex: All
Age: 40 - 70+
Code: NCT05390892
Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
for
Alzheimer Disease
Location: Huntsville AL
Sponsor: Eli Lilly and Company
Sex: All
Age: 60+
Code: NCT06566170
Recruiting
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
for
Waldenstrom Macroglobulinemia
Location: Huntsville AL, Mobile AL, Las Vegas NV,
Sponsor: BeiGene
Sex: All
Age: 18+
Code: NCT05640102
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
for
Carcinoma, Non-Small-Cell Lung
Location: Huntsville AL, Chattanooga TN, Nashville TN, Atlanta GA,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06667076
Phase2, Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Location: Huntsville AL, Nashville TN, Charlotte NC, St Louis MO,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07218380
Phase3, Recruiting
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
for
Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC),
Location: Huntsville AL, Knoxville TN, Athens GA, New Lenox IL,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07489066
Phase2, Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
for
Metastatic Castration Sensitive Prostate Cancer (mCSPC),
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
for
Triple Negative Breast Cancer
Location: Huntsville AL, Birmingham AL, Marietta GA, Atlanta GA,
Sponsor: Gilead Sciences
Sex: All
Age: 18+
Code: NCT05633654
Phase3, Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
for
Carcinoma, Non-Small-Cell Lung
Location: Huntsville AL, Chattanooga TN, Nashville TN, Atlanta GA,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06890598
Phase3, Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer